Tissue residue depletion of firocoxib in horses after oral administration

AGRO 9

Valerie Kvaternick, valerie.kvaternick@merial.com1, Bruce Kunkle2, and Alisa Khunachak1. (1) PKDM, Merial, 631 Route 1 South, North Brunswick, NJ 08902, (2) Clinical Operations, Merial, 6498 Jade Road, Fulton, MO 65251
Firocoxib (EQUIOXX® Merial) is a newly approved second generation coxib for the relief of pain and inflammation associated with osteoarthritis in the horse. To support registration of the product in the European Union, a tissue residue study was conducted. Twenty-five horses were administered 14 consecutive daily oral doses of firocoxib (0.1 mg/kg). The animals were divided into groups of five for tissue collection 0, 1, 3, 7, or 14 days post last dose. The kidneys, liver, and samples of muscle and fat were collected for processing and analyzed using a GLP validated determinative method. Residue levels were calculated for each tissue from each animal at each time point. The average kidney and muscle residue levels were below the limit of quantitation 14 days post last dose. The average residues in liver (target tissue) and fat were 63.7 and 20.5 ng/g, respectively. The method limit of quantitation is 5 ng/g.
 

Agrochemical Residue & Metabolism Chemistry
8:55 AM-11:20 AM, Sunday, August 19, 2007 BCEC -- 259B, Oral

Division of Agrochemicals

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007